128 related articles for article (PubMed ID: 16936459)
1. Preliminary individualized chemotherapy for malignant astrocytomas based on O6-methylguanine-deoxyribonucleic acid methyltransferase methylation analysis.
Watanabe T; Katayama Y; Ogino A; Ohta T; Yoshino A; Fukushima T
Neurol Med Chir (Tokyo); 2006 Aug; 46(8):387-93; discussion 393-4. PubMed ID: 16936459
[TBL] [Abstract][Full Text] [Related]
2. O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course.
Watanabe T; Katayama Y; Komine C; Yoshino A; Ogino A; Ohta T; Fukushima T
Int J Cancer; 2005 Feb; 113(4):581-7. PubMed ID: 15455376
[TBL] [Abstract][Full Text] [Related]
3. Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy.
Kamiryo T; Tada K; Shiraishi S; Shinojima N; Kochi M; Ushio Y
Neurosurgery; 2004 Feb; 54(2):349-57; discussion 357. PubMed ID: 14744281
[TBL] [Abstract][Full Text] [Related]
4. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas.
Komine C; Watanabe T; Katayama Y; Yoshino A; Yokoyama T; Fukushima T
Brain Pathol; 2003 Apr; 13(2):176-84. PubMed ID: 12744471
[TBL] [Abstract][Full Text] [Related]
6. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
Balaña C; Ramirez JL; Taron M; Roussos Y; Ariza A; Ballester R; Sarries C; Mendez P; Sanchez JJ; Rosell R
Clin Cancer Res; 2003 Apr; 9(4):1461-8. PubMed ID: 12684420
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene.
Nakamura M; Watanabe T; Yonekawa Y; Kleihues P; Ohgaki H
Carcinogenesis; 2001 Oct; 22(10):1715-9. PubMed ID: 11577014
[TBL] [Abstract][Full Text] [Related]
8. [Resent advances in chemotherapy for malignant brain tumors].
Shibui S
Gan To Kagaku Ryoho; 2005 Apr; 32(4):442-7. PubMed ID: 15853207
[TBL] [Abstract][Full Text] [Related]
9. [Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Zhang JP; Shi HL; Sai K; Yue WY; Mu YG; Zhang XH; Chen ZP
Ai Zheng; 2006 Dec; 25(12):1533-7. PubMed ID: 17166381
[TBL] [Abstract][Full Text] [Related]
10. [Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Zheng CQ; Ji SP; Gong F; Li AM; Tai JL; Zhang YP
Ai Zheng; 2009 Jun; 28(6):575-80. PubMed ID: 19635193
[TBL] [Abstract][Full Text] [Related]
11. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
12. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
13. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
14. In situ detection of O6-methylguanine-DNA methyltransferase messenger RNA in paraffin-embedded human astrocytic tumor tissues by nested in situ RT-PCR is useful in predicting chemotherapy-resistance of tumors.
Ohe N; Saio M; Kijima M; Tamakawa N; Suwa T; Kojima Y; Yano H; Kaku Y; Iwama T; Shinoda J; Sakai N; Takami T
Int J Oncol; 2003 Mar; 22(3):543-9. PubMed ID: 12579307
[TBL] [Abstract][Full Text] [Related]
15. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of O6-methylguanine-DNA methyltransferase gene expression in gliomas by platinum compounds.
Tanaka S; Kobayashi I; Utsuki S; Oka H; Yasui Y; Fujii K
Oncol Rep; 2005 Nov; 14(5):1275-80. PubMed ID: 16211296
[TBL] [Abstract][Full Text] [Related]
17. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.
Möllemann M; Wolter M; Felsberg J; Collins VP; Reifenberger G
Int J Cancer; 2005 Jan; 113(3):379-85. PubMed ID: 15455350
[TBL] [Abstract][Full Text] [Related]
18. Induction of the DNA repair gene O6-methylguanine-DNA methyltransferase by dexamethasone in glioblastomas.
Ueda S; Mineta T; Nakahara Y; Okamoto H; Shiraishi T; Tabuchi K
J Neurosurg; 2004 Oct; 101(4):659-63. PubMed ID: 15481722
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
